Leyden Labs develops nasal sprays that deliver antibodies directly to the nasal mucosa to provide immediate protection against respiratory viruses, preventing initial infections and onward transmission. Their technology targets conserved epitopes across viral families, offering broad protection against existing and emerging strains, regardless of an individual's immune history.
Funding
$244.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFounders
Product
Problem
Respiratory viruses, including influenza and COVID-19, exhibit asymptomatic spread, making it difficult to prevent initial infections and subsequent transmission. Current methods often fail to provide immediate protection at the point of entry, the nasal mucosa, leaving individuals vulnerable to infection regardless of their immune history.
Solution
Leyden Labs develops nasal sprays that deliver antibodies directly to the nasal mucosa, providing immediate antiviral protection against respiratory viruses. This approach aims to stop the initial infection, preventing onward transmission, and offers broad protection against existing and emerging viral strains. By targeting conserved epitopes across viral families, the sprays provide universal protection, independent of an individual's immune history or comorbidities. The company's technology harnesses mucosal immunity, optimizing the administration of intranasally-delivered antibodies to efficiently target invading virus particles and engage the immune system.
Target Audience
The primary target audience includes individuals seeking immediate protection against respiratory viruses, as well as public health organizations and governments preparing for future pandemics.
Features
- Nasal spray formulation for direct delivery of antibodies to the nasal mucosa.
- Broad-spectrum protection targeting conserved epitopes across multiple respiratory viruses.
- Designed to prevent initial infection and onward transmission of viruses.
- Utilizes modified antibodies optimized for mucosal administration.
- Lead program, PanFlu™, is currently in clinical trials.
- Aims for accessible and self-administrable products for autonomous protection.